Development of a CD-MEKC method for investigating the metabolism of tamoxifen by flavin-containing monooxygenases and the inhibitory effects of methimazole, nicotine and DMXAA.
Duygu Yeniceli, Xiaolan Deng, Erwin Adams, Dilek Dogrukol-Ak, Ann Van Schepdael
Index: Electrophoresis 34(3) , 463-70, (2013)
Full Text: HTML
Abstract
A selective and low-cost CD-MEKC method under acidic conditions was developed for investigating the N-oxygenation of tamoxifen (TAM) by flavin-containing monooxygenases (FMOs). The inhibitory effects of methimazole (MMI), nicotine and 5,6-dimethylxanthenone-4-acetic acid (DMXAA) on the given FMO reaction were also evaluated; 100 mM phosphate buffer (pH 8.6) was used for performing the enzymatic reaction and the separation of TAM and its metabolite tamoxifen N-oxide (TNO) was obtained with a BGE consisting of 100 mM phosphoric acid solution adjusted to pH 2.5 with triethanolamine containing 50 mM sodium taurodeoxycholate, 20 mM carboxymethyl β-CD and 20% ACN. The proposed method was applied for the kinetics study of FMO1 using TAM as a substrate probe. A Michaelis-Menten constant (K(m)) of 164.1 μM was estimated from the corrected peak area of the product, TNO. The calculated value of the maximum reaction velocity (V(max)) was 3.61 μmol/min/μmol FMO1; 50% inhibitory concentration and inhibition constant (K(i)) of MMI, the most common alternate substrate FMO inhibitor, were evaluated and the inhibitory effects of two other important FMO substrates, nicotine and DMXAA, a novel anti-tumour agent, were investigated.© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Related Compounds
Related Articles:
2010-01-01
[Chem. Res. Toxicol. 23 , 171-83, (2010)]
2011-12-01
[J. Sci. Ind. Res. 65(10) , 808, (2006)]
The Japanese toxicogenomics project: application of toxicogenomics.
2010-02-01
[Mol. Nutr. Food. Res. 54 , 218-27, (2010)]
Developing structure-activity relationships for the prediction of hepatotoxicity.
2010-07-19
[Chem. Res. Toxicol. 23 , 1215-22, (2010)]
A predictive ligand-based Bayesian model for human drug-induced liver injury.
2010-12-01
[Drug Metab. Dispos. 38 , 2302-8, (2010)]